Continuous Crystallization Patents: Leaders, Trends & White Space 2026
- Filing has fallen 79% from 2021 to 2024, the last complete year in scope — a sharp pullback from the 2017 peak of 67 filings, not a plateau.
- The leader holds 107 records, but the top 5 assignees combined account for only 16.3% of all 1,307 records — no single owner controls the field.
- Separation and reaction-engineering classes (B01D, B01J) outweigh medicinal-preparation claims (A61K), showing most of the documented invention sits in the crystallizer hardware and process control, not the molecule.
Filing growth compares 2021 (43 records) with 2024 (9) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,307 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Continuous crystallization replaces batch cooling or evaporative crystallizers with steady-state or plug-flow equipment that runs for extended periods without stopping to empty and reload. Patent activity in this dataset centers on the operational problems that keep such systems running: residence time control, encrustation and fouling management, startup transients, and slurry transfer between stages. The scope spans 1,307 published records filed between 2015 and mid-2026.
The dataset draws on documents indexed under mixed suspension crystallizer and continuous crystallization terminology, cross-referenced against process-engineering terms like plug flow crystallizer and steady state operation. That combination pulls in both pharmaceutical active-ingredient crystallization and adjacent process industries that share the same equipment vocabulary, which is visible in the IPC spread below.
Filing trend and technology composition
Two views of the same 1,307-record corpus: how filing activity has moved year over year, and which IPC subclasses the claims sit in.
Filing trend, 2017–2026
Filings peaked at 67 in 2017 and declined to 3 by 2026, though the two most recent years are still incomplete due to publication lag. The clearest complete-year comparison is 2021 (43 filings) against 2024 (9 filings) — a 79% drop over three years, and the figure this page's growth statement is built on.
IPC subclass composition
C07C (acyclic and carbocyclic compounds) and B01D (separation processes) each cover roughly a quarter of the 1,307 records, with B01J (catalytic and physical processes) close behind. A61K (medicinal preparations) and C07D (heterocyclic compounds) sit lower, at under 10% each — evidence that the patent activity in this search concentrates on the crystallizer process itself rather than on the pharmaceutical molecule being crystallized. Records can carry more than one class, so these shares sum above 100%.
Shares are the percentage of the 1,307 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Continuous Crystallization of Active Ingredients with Eureka
This page is one run against one query. Ask Eureka your own question about continuous crystallization of active ingredients and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative filing
Anti-fouling control for plug flow crystallizers (US20170312795A1)
Filed by Purdue Research Foundation, this application describes a plug flow crystallizer with independently controlled heating/cooling elements along its channel, run by a controller that implements a temperature profile designed to grow crystals in one segment and dissolve encrustation in another — addressing fouling directly inside the flow path rather than through downstream cleaning cycles.Filed 2017-11-02. Encrustation control is one of the recurring operational problems this search string was built to surface.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US3234258A | Sulfation of alpha olefins | 430 |
| 2 | US5314506A | Crystallization method to improve crystal structure and size | 321 |
| 3 | US5175355A | Improved process for recovery of purified terephthalic acid | 238 |
| 4 | US3931305A | Terephthalic acid recovery by continuous flash crystallization | 190 |
| 5 | US3452088A | Terephthalic acid recovery | 153 |
| 6 | US5756833A | Catalytic purification and recovery of dicarboxylic aromatic acids | 143 |
| 7 | US4500732A | Process for removal and recycle of p-toluic acid from terephthalic acid crystallizer solvent | 132 |
| 8 | US20120270107A1 | Nickel-cobalt-manganese complex hydroxide particles and method for producing same, positive electrode active … | 116 |
| 9 | US5738834A | System for removal of hydrogen sulfide from a gas stream | 113 |
| 10 | EP0419400A2 | Process for crystallization of polyethylene naphthalate | 110 |
Citation counts favor older documents simply because they have had more time to be cited; treat this as a signal of influence within the searched corpus, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say
Three figures from the dataset that change how you should read the rest of the page.
No single assignee dominates
The leading assignee holds 107 records, but the next four combined bring the top-5 share to only 16.3% of all 1,307 records in scope. The top 10 combined reach 23.5%. That leaves a long tail of single- and few-filing entrants holding most of the field.
Activity has pulled back sharply since 2017
From a 2017 peak of 67 filings, activity fell to 43 in 2021 and 9 by 2024 — a 79% drop across those three complete years. 2025 and 2026 figures are still filling in under an approximate 18-month publication lag, so they should not yet be read as a continuation of the decline.
Process hardware outweighs the active ingredient
C07C and B01D each cover roughly a quarter of the 1,307 records, while A61K (medicinal preparations) sits at 9.7%. Most of the documented claim space addresses the crystallizer and its operation, not the drug substance being made.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to continuous crystallization of active ingredients, with the prior art for and against each one.
Who holds the ground, and where it opens up
The ranked leaders account for a modest share of total filings, and recent-year momentum has gone quiet across the assignees who built the largest positions.
A clear leader, but not a lock on the field
The top-ranked assignee's 107 records are well ahead of fifth place (22) and tenth place (18), showing a steep drop-off rather than a cluster of comparable rivals just behind the leader.
Momentum has gone quiet at the top
Several of the assignees with the largest historical positions show zero filings in the latest year of the dataset. That is consistent with the broader decline from the 2017 peak, though the most recent years are still incomplete due to publication lag.
Co-filing is limited and concentrated
Only 10 co-assignee pairs appear in the dataset, with the strongest pairings repeating between the same handful of organisations. Co-development is the exception here, not the norm.
| Assignee | Recent year | YoY |
|---|---|---|
| Sumitomo Metal Mining Co., Ltd. | 0 | — |
| Mitsubishi Chemical Corporation | 0 | — |
| Pfizer Products Inc. | 0 | — |
| Shell Internationale Research Maatschappij B.V. | 0 | — |
| A.E. Staley Manufacturing Co. | 0 | — |
| Max Planck Gesellschaft zur Förderung der Wissenschaften e.V. | 0 | — |
| Mitsubishi Gas Chemical Company, Inc. | 0 | — |
| GE Healthcare AS | 0 | — |
Where to take this next
The landscape points to specific next steps depending on whether you are scoping freedom to operate or looking for a filing position.
Check the under-claimed branches before drafting claims
Slurry transfer, startup transients and in-line fouling detection show up less in the top-cited records than crystallizer hardware itself, suggesting room for narrower process claims.
Explore white space in EurekaWatch for a rebound once 2025-2026 data settles
Because publication lags filing by around 18 months, the apparent decline through 2026 needs another filing cycle before it can be called a real slowdown rather than a data gap.
Track filing trends in EurekaCommon questions about this landscape
The dataset ranks 100 assignees by record count, with the leader holding 107 records against 22 for fifth place and 18 for tenth place. However, the top 5 assignees combined account for only 16.3% of all 1,307 records in scope, and the top 10 combined reach 23.5%. That means most of the field's activity sits with a long tail of smaller filers rather than a handful of dominant owners, so a full freedom-to-operate check needs to look well beyond the largest names.
Filings peaked in 2017 at 67 and fell to 9 by 2024, a 79% drop across the last three complete years (2021 to 2024). The years 2025 and 2026 show far fewer filings still, but that reflects roughly 18 months of publication lag rather than a confirmed continuation of the decline. Anyone using this trend to decide whether to enter the space should treat 2024 as the most recent reliable data point.
The two largest IPC subclasses are C07C (acyclic and carbocyclic compounds) and B01D (separation processes), each covering close to a quarter of the 1,307 records, followed by B01J (catalytic and physical processes) at 15.5%. Medicinal-preparation claims under A61K make up only 9.7% of records, and heterocyclic compound claims under C07D 9.6%. This split shows that most of the patented invention addresses the crystallizer process and equipment rather than the pharmaceutical molecule itself, and because records can carry multiple classes, these shares sum above 100%.
This Purdue Research Foundation application covers a plug flow crystallizer with independently controlled heating and cooling elements along its channel, run by a controller implementing a temperature profile that grows crystals in one channel segment and dissolves encrustation in another. It is specific to using temperature zoning as the anti-fouling mechanism inside the flow channel itself. Designs that manage fouling through mechanical scraping, ultrasonic treatment, or periodic flow reversal rather than in-channel temperature zoning would sit outside its core claim language, though a full clearance opinion should confirm current claim scope and status.
The citation and IPC pattern suggests thinner coverage in slurry transfer between crystallizer stages, startup transient control specific to plug flow geometries, and in-line encrustation detection paired with automated cleaning response. These sit adjacent to the heavily claimed core of crystallizer hardware and separation processes (B01D, B01J) but appear less often among the most-cited records. A first claim in these areas would likely need to specify the sensing or control mechanism precisely, since broad process claims in the core area are already dense with prior art.
Research Continuous Crystallization of Active Ingredients in depth with Eureka
Go past this page: query the whole continuous crystallization of active ingredients corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.